To translate our BONLAC screen in the brains of FXS model mice into clinically-relevant targets for biomarkers, we determined whether the candidate proteins could be identified in blood and asked whether: (1) they are expressed and could be detected reliably, (2) the expression levels of the proteins were sensitive to treatments that have been shown to affect behavior in Fmr1 KO mice, and (3) differential expression of the proteins could be detected in FXS patients (Figs 4 and 5). Here, FMR1 is linked to fragile X syndrome.